CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Spruce Biosciences, Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Spruce Biosciences, Inc
611 Gateway Boulevard, Suite 740
Phone: (302) 636-5400p:302 636-5400 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: SPRBSPRB
Business Summary
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. It has a diverse portfolio of product candidates addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. Its pipeline consists of TA-ERT, Tildacerfont and Cortibon, and SPR202. TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. Tildacerfont has the potential to address hyperactive brain corticotropin-releasing factors neurotransmission and aberrant functioning of the hypothalamus-pituitary-adrenal axis in patients with MDD. SPR202 focuses on the treatment of Congenital Adrenal Hyperplasia and other indications.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Michael G.Grey 72 1/3/2022 1/1/2016
President, Chief Financial Officer Samir M.Gharib 42 1/1/2022 5/1/2020
Chief Executive Officer, Director JavierSzwarcberg 55 1/3/2022 1/1/2022
6 additional Officers and Directors records available in full report.

Business Names
Business Name
SPRB
SPRBD

General Information
Number of Employees: 8 (As of 12/31/2025)
Outstanding Shares: 2,702,043 (As of 4/21/2026)
Shareholders: 43
Stock Exchange: NASD
Federal Tax Id: 812154263
Fax Number: (302) 636-5454


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, May 11, 2026